Kuros Biosciences Ltd. announced that Dr. Ivan Cohen-Tanugi has been appointed as chief executive officer with effect as of April 13, 2017. Dr. Cohen-Tanugi will be proposed for election to the board of directors at the next general meeting. He succeeds Didier Cowling, who continues to serve the company as president and remains a member of the executive committee and the board. Dr. Cohen-Tanugi joins Kuros with more than 20 years of experience in leadership roles in the life sciences industry. He held various managing positions at Sanofi, Roche, Amgen, Teva, Eyevensys and Stallergenes-Greer including as Head of Amgen Europe Nephrology, General Manager Teva North America Biologics & Specialty and CEO of Eyevensys.